ELAN Stock Forecast & Price Target

Elanco Animal Health is benefitting from a clear inflection in execution, with 2Q revenue of $1,368M, adjusted EBITDA of $288M, and adjusted EPS of $0.34 all beating expectations, while management also raised FY26 revenue to $5,090M-$5,140M, EBITDA to $1,010M-$1,035M, and EPS to $1.10-$1.16. Its bullish case is reinforced by multiple product catalysts—Zenrelia, Quattro, and Befrena—alongside a next wave innovation portfolio with $2B+ peak sales potential, supporting higher growth, margin expansion, and deleveraging. Pricing discipline appears intact as competition is increasingly centered on portfolio selling and targeted marketing, while strong pet and farm-animal demand across a global footprint in over 90 countries provides a diversified, resilient base.

Elanco Animal Health is facing a bearish setup because its industry is intensely competitive, with rivals advancing R&D, generics pressuring pricing, and disruptive innovation potentially eroding demand across companion and food-animal categories. Regulatory bans on antibiotics and productivity products, plus disease outbreaks, customer consolidation, manufacturing issues, and weather-related volatility, can all disrupt volumes, delay launches, and raise costs, while pipeline setbacks and weaker blockbuster ramps could weigh on sales and EPS growth. Its global exposure also adds foreign exchange, emerging-market, and political risk, and concerns around cannibalization, commoditization in K9 markets, and soft pet spending further undermine confidence in future performance.